Tag: Asthma and COPD Market Size

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Value Growth And Long-Term Outlook

The asthma and chronic obstructive pulmonary disease (copd) drugs market size has demonstrated significant growth in recent years. This market is projected to expand from $35.66 billion in 2025 to $39.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.6%. The historical expansion can be attributed to factors such as rising smoking prevalence, urban air pollution, enhanced hospital-based respiratory care, the adoption of inhaler technology, and an increase in asthma diagnoses.

The asthma and chronic obstructive pulmonary disease (copd) drugs market size is projected for substantial expansion over the coming years, anticipated to reach $55.67 billion in 2030, driven by a compound annual growth rate (CAGR) of 9.3%. This expected growth throughout the forecast period is attributable to factors like biologic drug innovation, an aging population, deteriorating air quality, developments in personalized respiratory medicine, and the emergence of homecare respiratory solutions. Significant trends during this period include a rising adoption of combination inhaler therapies, increased use of long-acting bronchodilators, the expansion of biologic treatments for severe asthma, a shift towards home-based respiratory management, and a growing demand for generic inhalation drugs.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Growth Backed By Core Demand Fundamentals

The rising incidence of smoking is anticipated to fuel the expansion of the asthma and COPD drugs market in the future. Smoking involves the practice of using tobacco items by inhaling their smoke, potentially leading to severe health problems such as lung cancer and heart disease. The growing occurrence of smoking is primarily fueled by social factors, wherein peer pressure, cultural standards, and social surroundings encourage individuals to begin and persist in smoking. Asthma and chronic obstructive pulmonary disease (COPD) drugs play a role in lessening the respiratory harm caused by smoking through mechanisms like reducing inflammation, relaxing airway muscles, and enhancing airflow, thereby alleviating symptoms and improving lung function. As an illustration, a 2024 study on smoking patterns among young individuals, conducted by the European Respiratory Society’s (ERS), a Switzerland-based non-profit body, revealed a significant surge in smoking rates, climbing from 22.5% of participants in 2022 to 40.1% in 2024. Consequently, the increasing prevalence of smoking is propelling the growth of the asthma and COPD drugs market.

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segments: Where Is Growth Concentrated?

The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Growth Trends Reshaping The Competitive Landscape

Leading companies within the asthma and chronic obstructive pulmonary disease (COPD) drugs market are increasingly prioritizing the integration of cutting-edge drug-combination therapies, such as rescue inhalers that combine short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS). This strategic focus aims to deliver enhanced patient outcomes, including the prevention of severe asthma attacks, more effective inflammation management, and improved overall disease control. A SABA–ICS rescue inhaler functions by merging a short-acting beta-agonist, which provides rapid relief by relaxing airway muscles, with an inhaled corticosteroid, which targets and reduces chronic airway inflammation. This combination offers a dual advantage, delivering both immediate symptom alleviation and crucial anti-inflammatory effects. For instance, in January 2024, AstraZeneca, a UK–based biopharmaceutical company, introduced AIRSUPRA (albuterol/budesonide) into the US market. This fixed-dose SABA-ICS rescue inhaler is engineered to alleviate asthma symptoms and preempt sudden severe respiratory distress, leveraging its dual-component formula delivered through pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA contributes to superior acute symptom relief while concurrently tackling airway inflammation, thereby lowering the likelihood of severe asthma exacerbations and promoting enhanced asthma management.

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Key Participants And Competitive Landscape

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

View The Full Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for asthma and chronic obstructive pulmonary disease (COPD) medications has experienced robust expansion over recent years. Projected to rise from $35.66 billion in 2025 to $39.07 billion in 2026, this growth represents a compound annual growth rate (CAGR) of 9.6%. Historical progress has been driven by factors such as increasing rates of smoking, urban air pollution, respiratory care provided in hospital settings, the widespread adoption of inhaler technology, and a rise in asthma diagnoses.

The respiratory drug market, covering asthma and chronic obstructive pulmonary disease (COPD), is projected to experience robust expansion in the coming years. It is anticipated to reach a value of $55.67 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.3%. Key factors driving this forecasted growth include innovation in biologic drugs, an aging population, worsening air quality, the emergence of personalized respiratory therapies, and a shift toward home-based care solutions. Notable trends shaping this period comprise the rising use of combination inhaler therapies, a greater emphasis on long-acting bronchodilators, the expanding role of biologics in managing severe asthma, a move toward managing respiratory conditions at home, and an escalating demand for affordable generic inhalation medications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Demand Drivers: What Is Fueling Industry Growth?

The rising frequency of smoking is anticipated to advance the expansion of the asthma and COPD drugs market in the foreseeable future. Smoking is defined as the practice of consuming tobacco products through inhaling smoke, a habit that causes severe health problems like lung cancer and heart disease. This growing trend in smoking is largely fueled by social influences, including peer pressure, cultural standards, and social settings that drive individuals to begin and persist in smoking. Medications for asthma and chronic obstructive pulmonary disease (COPD) counteract the respiratory damage from smoking by decreasing inflammation, relaxing airway muscles, and enhancing airflow, which eases symptoms and boosts lung performance. In 2024, the European Respiratory Society (ERS), a Switzerland-based nonprofit, released a study on youth smoking trends, revealing a significant rise from 22.5% of participants in 2022 to 40.1% in 2024. Consequently, the increasing prevalence of smoking is fueling the growth of the asthma and COPD drugs market.

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segment Landscape: Which Areas Lead Market Development?

The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Innovation Trends: Which Developments Are Transforming The Industry?

Major players in the asthma and chronic obstructive pulmonary disease (COPD) drug market are increasingly turning to innovative combination therapies, including short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers, to deliver benefits such as preventing severe asthma episodes, better managing inflammation, and supporting more effective disease control. A SABA–ICS rescue inhaler merges a short-acting beta-agonist, which quickly eases airway muscle tension to alleviate symptoms, with an inhaled corticosteroid, which combats persistent airway inflammation, thus providing dual advantages—swift symptom relief coupled with an anti-inflammatory effect. For example, in January 2024, AstraZeneca, a biopharmaceutical firm headquartered in the UK, introduced AIRSUPRA (albuterol/budesonide) in the United States. This fixed-dose SABA-ICS rescue inhaler is aimed at treating asthma symptoms and averting sudden serious breathing issues, with its two-component formulation delivered through pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA not only enhances quick symptom relief but also targets airway inflammation concurrently, lowering the chance of severe asthma flare-ups and improving overall asthma management.

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Industry Leaders And Market Competition

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

Access The Complete Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market During The 2026–2030 Period?

The asthma and chronic obstructive pulmonary disease (copd) drugs market size has shown robust expansion in recent years. It is projected to expand from $35.66 billion in 2025 to $39.07 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. The expansion observed in the historic period can be attributed to several factors, including rising smoking prevalence, urban air pollution, advancements in hospital-based respiratory care, the adoption of inhaler technology, and an increase in asthma diagnosis.

The asthma and chronic obstructive pulmonary disease (COPD) drugs market size is projected to undergo significant expansion in the coming years. It is foreseen to increase to $55.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. The drivers behind this growth within the forecast period comprise biologic drug innovation, the aging population, worsening air quality, advancements in personalized respiratory medicine, and the emergence of homecare respiratory solutions. Prominent trends for the forecast period involve an escalated utilization of combination inhaler therapies, the increasing embrace of long-acting bronchodilators, the widespread application of biologic therapies for severe asthma, a move towards managing respiratory conditions in home settings, and a heightened demand for generic inhalation drugs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

Which Core Factors Are Supporting The Expansion Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The rising incidence of smoking is projected to fuel the expansion of the asthma and COPD drugs market in the future. Smoking involves the practice of using tobacco by inhaling its smoke, a habit known to cause severe health problems like lung cancer and heart disease. This growing prevalence of smoking primarily stems from social influence, as peer pressure, societal norms, and social settings often prompt individuals to begin and persist with smoking. Medications for asthma and chronic obstructive pulmonary disease (COPD) work to lessen the respiratory harm from smoking by decreasing inflammation, relaxing airway muscles, and enhancing airflow, consequently easing symptoms and boosting lung function. For instance, in 2024, data from a study by the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, on youth smoking trends revealed a significant increase in smoking rates, climbing from 22.5% of respondents in 2022 to 40.1% in 2024. Consequently, the expanding prevalence of smoking is accelerating the growth of the asthma and COPD drugs market.

Which Segment Divisions Form The Structure Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

What Trends Are Shaping The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Structure?

Leading companies in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are prioritizing the integration of innovative drug-combination therapies, such as short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers. This strategic focus aims to enhance benefits like the prevention of severe asthma attacks, better inflammation control, and more effective overall disease management. A SABA–ICS rescue inhaler combines a short-acting beta-agonist, which quickly relaxes airway muscles for symptom relief, with an inhaled corticosteroid, which reduces underlying airway inflammation, providing dual capabilities of immediate symptom alleviation alongside anti-inflammatory action. For instance, in January 2024, AstraZeneca, a UK–based biopharmaceutical company, launched AIRSUPRA (albuterol/budesonide) in the US. This fixed-dose SABA-ICS rescue inhaler is designed to treat asthma symptoms and help prevent sudden severe breathing problems, featuring its dual-component formulation delivered via pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA improves acute symptom relief while simultaneously addressing airway inflammation, thereby decreasing the risk of severe asthma exacerbations and enhancing overall asthma control.

Who Are The Companies Shaping The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Landscape?

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

Access The Complete Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

Which Regional Market Leads The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

Browse Through More Reports Similar to the Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2026, By The Business Research Company

Anti Asthmatics And Copd Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Digital Dose Inhalers Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-dose-inhalers-global-market-report

Inhaled Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Projected To Reach By 2030?

The asthma and chronic obstructive pulmonary disease (copd) drugs market has demonstrated significant expansion over recent years. Forecasts show that its size is set to climb from $35.66 billion in 2025 to $39.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.6%. This historical increase can be linked to factors like rising smoking prevalence, urban air pollution, hospital-based respiratory care, the adoption of inhaler technology, and an increase in asthma diagnosis.

The market for asthma and chronic obstructive pulmonary disease (COPD) drugs is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $55.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. Key drivers contributing to this growth during the forecast period include advancements in biologic drugs, an increasingly elderly global population, declining air quality, the emergence of personalized respiratory medicine, and the availability of homecare respiratory solutions. Notable trends anticipated in this period encompass the heightened utilization of combination inhaler therapies, a wider uptake of long-acting bronchodilators, the broadening application of biologic treatments for severe asthma, a transition towards managing respiratory conditions at home, and an increasing appetite for generic inhalation medications.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

Which Key Drivers Are Affecting The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Development?

The rising incidence of smoking is anticipated to drive expansion in the asthma and COPD drugs market moving forward. Smoking describes the practice of consuming tobacco items through smoke inhalation, potentially resulting in severe health problems like lung cancer and heart disease. Social influence largely fuels the growing prevalence of smoking, with factors such as peer pressure, societal norms, and social surroundings motivating individuals to initiate and maintain smoking habits. Medications for asthma and chronic obstructive pulmonary disease (COPD) aid in counteracting the respiratory harm inflicted by smoking by lessening inflammation, relaxing airway muscles, and improving air circulation, thus easing symptoms and boosting lung performance. For example, in 2024, a study conducted by the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, on youth smoking trends revealed a significant surge in smoking rates, climbing from 22.5% of survey participants in 2022 to 40.1% in 2024. Consequently, the expanding prevalence of smoking is propelling the growth of the asthma and COPD drugs market.

How Is The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segmented Across Different Segment Categories?

The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

What Trends Are Transforming The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

Major companies within the asthma and chronic obstructive pulmonary disease (COPD) drugs market are increasingly focusing on integrating innovative drug-combination therapies, such as short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers. This focus aims to provide enhanced benefits, including the prevention of severe asthma attacks, improved inflammation control, and better overall disease management. A SABA–ICS rescue inhaler combines a short-acting beta-agonist, which rapidly relaxes airway muscles to alleviate symptoms, with an inhaled corticosteroid that reduces underlying airway inflammation. This dual action provides immediate symptom relief alongside anti-inflammatory effects. For instance, in January 2024, AstraZeneca, a UK-based biopharmaceutical company, launched AIRSUPRA (albuterol/budesonide) in the US. This fixed-dose SABA-ICS rescue inhaler is designed to treat asthma symptoms and help prevent sudden severe breathing problems, featuring its dual-component formulation delivered via pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA improves acute symptom relief while simultaneously addressing airway inflammation, thereby reducing the risk of severe asthma exacerbations and enhancing overall asthma control.

Which Organizations Play A Role In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Landscape?

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

Get The Full Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

Which Region Holds The Highest Market Share In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

Browse Through More Reports Similar to the Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2026, By The Business Research Company

Anti Asthmatics And Copd Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Digital Dose Inhalers Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-dose-inhalers-global-market-report

Inhaled Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Expected To Change Between 2026 And 2030?

The market for asthma and chronic obstructive pulmonary disease (copd) drugs has experienced significant expansion recently. This market is projected to expand from $35.66 billion in 2025 to $39.07 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. Historically, this growth has been driven by factors such as increasing smoking prevalence, urban air pollution, developments in hospital-based respiratory care, the uptake of inhaler technology, and an increase in asthma diagnoses.

The asthma and chronic obstructive pulmonary disease (copd) drugs market is projected to experience substantial expansion over the upcoming years. Its valuation is forecast to reach $55.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. This anticipated growth during the projection period stems from factors such as innovations in biologic drugs, an increasingly elderly populace, declining air quality, the advancement of personalized respiratory medicine, and the availability of homecare respiratory solutions. Key developments anticipated within this timeframe involve a rise in the application of combination inhaler treatments, the increasing uptake of long-acting bronchodilators, the broadening of biologic therapies for severe asthma cases, a movement towards managing respiratory conditions at home, and an escalating need for generic inhalation medications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

Which Major Factors Are Driving The Expansion Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The rising incidence of smoking is projected to spur the growth of the asthma and COPD drugs market moving forward. Smoking refers to the practice of consuming tobacco products by inhaling their smoke, which can lead to severe health problems such as lung cancer and heart disease. The growing prevalence of smoking is primarily fueled by social influence, wherein peer pressure, cultural norms, and social settings encourage individuals to begin and persist in smoking. Asthma and chronic obstructive pulmonary disease (COPD) drugs are instrumental in alleviating the respiratory damage induced by smoking, achieving this by lowering inflammation, relaxing airway muscles, and enhancing airflow, thereby relieving symptoms and boosting lung function. For example, in 2024, the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, published a study on youth smoking trends, revealing a significant increase in smoking rates, which rose from 22.5% of respondents in 2022 to 40.1% in 2024. Hence, the increasing prevalence of smoking is a key driver for the expansion of the asthma and COPD drugs market.

How Is The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Structured Across Different Segments?

The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

Which Trends Are Shaping The Future Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

Leading companies in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are concentrating on integrating innovative drug-combination therapies, such as short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers, to augment benefits like preventing severe asthma attacks, improving inflammation control, and supporting better overall disease management. A SABA–ICS rescue inhaler combines a short-acting beta-agonist, which rapidly relaxes airway muscles for symptom relief, with an inhaled corticosteroid, which reduces underlying airway inflammation, thereby enabling dual capabilities of immediate symptom relief alongside anti-inflammatory action. For instance, in January 2024, AstraZeneca, a UK–based biopharmaceutical company, launched AIRSUPRA (albuterol/budesonide) in the US, which is a fixed-dose SABA-ICS rescue inhaler engineered to treat asthma symptoms and help prevent sudden severe breathing problems, featuring its dual-component formulation delivered via pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA improves acute symptom relief while concurrently addressing airway inflammation, consequently lowering the risk of severe asthma exacerbations and enhancing overall asthma control.

Which Major Players Dominate The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

Read the full asthma and chronic obstructive pulmonary disease (copd) drugs market report here:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24472&type=smp

Browse Through More Reports Similar to the Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2026, By The Business Research Company

Anti Asthmatics And Copd Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Digital Dose Inhalers Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-dose-inhalers-global-market-report

Inhaled Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the asthma and chronic obstructive pulmonary disease (copd) drugs market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in 2026, and what figure is it projected to hit by 2030?

The asthma and chronic obstructive pulmonary disease (copd) drugs market size has seen significant expansion in recent years. This market is anticipated to expand from $35.66 billion in 2025 to $39.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.6%. The historical increase can be attributed to factors such as rising smoking prevalence, urban air pollution, the provision of hospital-based respiratory care, the adoption of inhaler technology, and an increase in asthma diagnoses.

The asthma and chronic obstructive pulmonary disease (copd) drugs market size is anticipated to undergo significant expansion in the upcoming years, projected to reach $55.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. This expected growth is primarily fueled by innovations in biologic drugs, an aging global population, worsening air quality, the evolution of personalized respiratory medicine, and advancements in homecare respiratory solutions. Prominent trends within this forecast period encompass an increased reliance on combination inhaler therapies, the wider adoption of long-acting bronchodilators, an expansion of biologic therapies for severe asthma, a transition towards managing respiratory conditions in home settings, and a growing demand for generic inhalation drugs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

Which Drivers Are Affecting Market Participation In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The rising occurrence of smoking is projected to fuel the expansion of the asthma and COPD drugs market in the future. Smoking describes the practice of using tobacco items through smoke inhalation, potentially resulting in severe health conditions like lung cancer and heart disease. This rising prevalence of smoking is largely influenced by social factors, including peer pressure, societal customs, and surroundings that motivate individuals to begin and persist with smoking. Medications for asthma and chronic obstructive pulmonary disease (COPD) work to lessen the respiratory harm from smoking through reducing inflammation, relaxing airway muscles, and improving air circulation, thus easing symptoms and boosting lung function. For example, a 2024 study by the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, on youth smoking trends revealed a significant jump in smoking rates, increasing from 22.5% of respondents in 2022 to 40.1% in 2024. Consequently, the growing incidence of smoking is boosting the expansion of the asthma and COPD drugs market.

What Segment Categories Are Covered In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

What Trends Are Driving The Growth Trajectory Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

Leading companies active in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are concentrating on integrating innovative drug-combination therapies, such as short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers. This focus aims to amplify benefits like preventing severe asthma attacks, improving inflammation control, and supporting more effective overall disease management. A SABA–ICS rescue inhaler combines a short-acting beta-agonist, which promptly relaxes airway muscles to relieve symptoms, with an inhaled corticosteroid, which works to lessen underlying airway inflammation, thereby providing dual capabilities for immediate symptom relief alongside anti-inflammatory action. For instance, in January 2024, AstraZeneca, a UK–based biopharmaceutical company, released AIRSUPRA (albuterol/budesonide) in the US. This fixed-dose SABA-ICS rescue inhaler is designed to treat asthma symptoms and help avert sudden severe breathing difficulties, featuring its dual-component formulation delivered through pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA improves acute symptom relief while simultaneously addressing airway inflammation, consequently reducing the risk of severe asthma exacerbations and enhancing overall asthma control.

Which Key Players Are Driving Competition In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

Which Region Is Projected To Lead The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market During The Forecast Period?

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24472&type=smp

Browse Through More Reports Similar to the Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2026, By The Business Research Company

Anti Asthmatics And Copd Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Digital Dose Inhalers Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-dose-inhalers-global-market-report

Inhaled Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry Expected To Reach By 2029, Starting From 2025 Levels?

The market for asthma and chronic obstructive pulmonary disease (COPD) drugs has demonstrated robust expansion over recent years. This market is anticipated to expand from $32.52 billion in 2024 to reach $35.66 billion by 2025, reflecting a compound annual growth rate (CAGR) of 9.6%. The expansion observed in prior periods can be attributed to several factors, including rising air pollution levels, increased rates of tobacco smoking, heightened public awareness of respiratory illnesses, the broader adoption of corticosteroids and bronchodilators, and an increase in healthcare expenditure.

The market for asthma and chronic obstructive pulmonary disease (copd) drugs is anticipated to experience substantial expansion over the coming years. This market is projected to reach $50.99 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.4%. This expansion throughout the forecast period can be attributed to factors such as the rising demand for personalized medicine, the increasing integration of biologics and cutting-edge therapies, a higher occurrence of environmental allergies, a surge in clinical trials and subsequent approvals, and the escalating prevalence of non-communicable diseases. Key trends anticipated during this period encompass smart inhalers enhanced by technology, the development of bronchodilators with dual actions, the merging of electronic health records (EHR) with drug-related data, breakthroughs in biopharmaceutical molecules, and the incorporation of machine learning into the process of drug discovery.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

Which Factors And Drivers Are Influencing The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In 2025?

The expanding occurrence of smoking is anticipated to fuel the expansion of the asthma and COPD drugs market in the future. Smoking refers to the practice of consuming tobacco products by inhaling the smoke, which can lead to serious health issues such as lung cancer and heart disease. The rising prevalence of smoking is primarily driven by social influence, where peer pressure, cultural norms, and social environments encourage individuals to start and continue smoking. Medications for asthma and chronic obstructive pulmonary disease (COPD) assist in mitigating the respiratory damage caused by smoking by reducing inflammation, relaxing airway muscles, and improving airflow, thereby alleviating symptoms and enhancing lung function. For instance, in 2024, according to the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, a study on smoking trends among young people showed a notable increase in smoking rates, rising from 22.5% of respondents in 2022 to 40.1% in 2024. Therefore, the growing frequency of smoking is driving the growth of the asthma and COPD drugs market.

What Are The Leading Segments Analyzed In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The asthma and chronic obstructive pulmonary disease (COPD) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Nasal, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

What Long-Term Trends Will Shape The Future Growth Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?

Leading companies in the asthma and COPD drugs market are prioritizing the creation of innovative formulations, such as fixed-dose combination (FDC) drugs, to enhance treatment adherence and therapeutic effectiveness. A fixed-dose combination (FDC) drug is a singular dosage form that incorporates two or more active ingredients, aiding in the management of asthma and COPD by merging bronchodilators and anti-inflammatories to improve symptom regulation and patient compliance. For example, in June 2022, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched Indamet, a novel fixed-dose combination (FDC) drug comprising Indacaterol, a long-acting beta-agonist (LABA), and Mometasone Furoate, an inhaled corticosteroid (ICS), intended for the treatment of uncontrolled asthma. Indamet represents the first FDC of its kind to be approved by the Drug Controller General of India (DCGI) and introduced in the nation, available in three strengths: Indacaterol 150 mcg combined with Mometasone 80 mcg, 160 mcg, or 320 mcg, administered once daily. This specific formulation is designed to optimize lung function, enhance symptom control, reduce the frequency of exacerbations, and improve treatment adherence among adult and adolescent patients aged 12 years and above.

Which Major Firms Are Strengthening Their Position In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?

Major companies operating in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy’s Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, Aurobindo Pharma

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

North America was the largest region in the asthma and COPD drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (COPD) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24472&type=smp

Browse Through More Reports Similar to the Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2025, By The Business Research Company

Anti Asthmatics And Copd Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Digital Dose Inhalers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digital-dose-inhalers-global-market-report

Inhaled Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Heading Into 2029?

In recent times, there has been substantial growth in the market size of asthma and chronic obstructive pulmonary disease (copd) drugs. The market, which is expected to climb from $32.52 billion in 2024 to $35.66 billion in 2025, will do so at a compound annual growth rate (CAGR) of 9.6%. Factors contributing to growth during the historic period include an increase in air pollution, escalated tobacco smoking rates, heightened awareness regarding respiratory illnesses, widespread use of corticosteroids and bronchodilators, and an increase in healthcare spending.

In the next few years, the market size for asthma and chronic obstructive pulmonary disease (copd) medication is slated to experience robust growth. The market is predicted to reach $50.99 billion in 2029, boasting a compound annual growth rate (CAGR) of 9.4%. The spike in growth throughout the forecast period can be attributed to factors such as the surging demand for customized medicine, the rise in biologics and advanced therapies adoption, the increasing incidence of environmental allergies, escalating clinical trials and approvals, and the growing concern of non-communicable diseases. Key trends moving forward include the rise of technologically-advanced smart inhalers, the development of dual-action bronchodilators, the integration of electronic health records (EHR) and drug data, advancements in biopharmaceutical molecules and the incorporation of machine learning for drug discovery.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

Which Factors Are Pushing The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Forward?

The soaring rates of tobacco usage are predicted to boost the expansion of the asthma and COPD drugs market in the future. The term smoking denotes the practice of using tobacco goods by inhaling the resultant smoke, and this can precipitate grave health conditions like lung cancer and heart disease. The surging rates of smoking are largely influenced by societal pressure, where peer influence, traditional norms, and social surroundings are prompting individuals to commence and maintain smoking. Drugs used to treat asthma and chronic obstructive pulmonary disease (COPD) work to lessen the respiratory impairment caused by smoking through the reduction of inflammation, the relaxation pulmonary muscles, and the enhancement of air circulation, thereby relieving symptoms and boosting lung functionality. For instance, a 2024 study on trends in smoking among younger individuals by the Switzerland-based non-profit entity, the European Respiratory Society (ERS), revealed a significant uptick in smoking rates, climbing from 22.5% of participating respondents in 2022 to 40.1% in 2024. Consequently, the rising rates of tobacco usage are fueling the expansion of the asthma and COPD drugs market.

Which Segment Held The Largest Share In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In 2025?

The asthma and chronic obstructive pulmonary disease (COPD) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Nasal, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

How Are Key Trends Driving Expansion In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?

The asthma and COPD drugs market is experiencing a shift as key players concentrate their efforts on creating novel arrangements such as fixed-dose combination (FDC) drugs, with the aim of enhancing patient compliance and medicinal effectiveness. FDC drugs contain multiple active constituents in a unified dose, and can contribute to managing asthma and COPD more effectively by coupling bronchodilators with anti-inflammatory agents, which optimizes symptom regulation and patient consistency. In June 2022, Glenmark Pharmaceuticals Limited, a pharmaceutical firm based in India, initiated the release of Indamet, an innovative FDC medication comprising Indacaterol, a long-term beta-agonist (LABA), and Mometasone Furoate, an inhaled corticosteroid (ICS), to treat unregulated asthma. Indamet represents the first FDC of its type to be sanctioned by India’s Drug Controller General (DCGI) for introduction into the Indian market. It comes in three potencies, i.e., Indacaterol 150 mcg combined with Mometasone 80 mcg, 160 mcg, or 320 mcg to be administered once a day. This concoction aims to enhance lung performance, better symptom management, lower occurrences of exacerbations, and uplift treatment adherence in adults and teenagers aged 12 years and above.

Which Organizations Are Driving Progress In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?

Major companies operating in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy’s Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, Aurobindo Pharma

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?

North America was the largest region in the asthma and COPD drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (COPD) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24472&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model